EN DE
Watch WOOJUNG BIO Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

WOOJUNG BIO Inc (215380) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of WOOJUNG BIO Inc stock KRW 904, price KRW 1,874, that is 51.8% below the price, quality 24 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7215380007

WB WOOJUNG BIO Inc logo Thin data Nov 3, 2026

WOOJUNG BIO Inc

215380 · KQ
Very expensive, weak quality

Our calculation puts a fair price 52% below what the stock costs today.

Revenue last quarter +33% vs. a year ago.
Moderate debt
Mixed vs. peers (6/11)
Fair value 903.99 KRW · Strongly overvalued
Quality 24/100
Weak Growth (revenue 5y +0.1 %/yr in KRW)
Loss-making · -9.1% net margin (TTM)
Negative free cash flow
Narrow moat 13/100 · thin data
Thin data
Watch WOOJUNG BIO Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

9,000 KRW 1,116 KRW Fair Value 903.99 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range 1,116 KRW – 9,000 KRW · fair‑value band 674.62 KRW – 1,349 KRW · the 1,874 KRW price screens above the 903.99 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow WOOJUNG BIO in your weekly email

Every Wednesday you see whether WOOJUNG BIO is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

WOOJUNG BIO, Inc. engages in the various research services in South Korea.

Show moreShow less

The company provides LAB CLOUD, a bio-specialized accelerator and research platform; and efficacy evaluation, clinical and histopathology, general and inhalation toxicology, behavioral test, bioanalytical, organoids, ADME, NMR analysis, SPR analysis, IND package, shared lab animal facility, breeding lab, microbial and environmental monitoring, and technical support services.

In addition, It offers construction and implementation, infection control, maintenance, laboratory and pharmaceutical equipment, and consumables and animal resourcing services. The company was founded in 1989 and is based in Hwaseong-si, South Korea.

Stock analysis

WOOJUNG BIO Inc (215380) currently trades at 1,874 KRW, while our model-based Fair Value estimate is 903.99 KRW, 52% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 674.62 KRW (bear) to 1,349 KRW (bull), the price of 1,874 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

WOOJUNG BIO Inc reported revenue of 37.6B KRW in FY2025 versus 31.2B KRW in FY2021, a compound +4.7%/yr. Reported net income was −5.5B KRW in FY2025.

Key figures

Market cap 30.7B KRW (≈ $22.7M) Micro · P/S ratio 0.86 · EPS (TTM) −220.56 KRW · Net margin −9.1% · Return on equity −14.6% · Return on assets (EBIT) −3.0% (5-year average) · Operating margin 3.9% · Revenue (TTM) 40.3B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 13 out of 100 (low confidence).

What moves the price

The share trades about 48% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −52%, 215380 screens richer than that median.

Fair Value models

Bear 674.62 KRW Fair Value 903.99 KRW Bull 1,349 KRW
Price 1,874 KRW · Downside -51.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 674.62 KRW 903.99 KRW 1,349 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 674.62 KRW 903.99 KRW 1,349 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 24/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 13
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 11
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 48
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 24
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 5/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
−13.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.1%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−14.2% (2020) → −9.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

215380 screens overvalued: fair value 52% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare WOOJUNG BIO Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 5/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside −51.8% · Below median
Profitability
Return on assets −6.4% · Above median
Net margin (12 months) −9.1% · Below median
Operating margin (12 months) 3.9% · Above median
Growth and dividend
Revenue growth (quarter YoY) 32.7% · Top 25%
Balance sheet
Debt / equity 1.31× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.31× · Cheaper than median
P/S (12 months) 0.76× · Cheapest 25%
EV/EBITDA 30.6× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)35 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 215380
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 215380
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 215380
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 215380
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 215380
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 215380
argenx SE ARGX $927.21 $908.40 −2% vs 215380
CSL Limited CSL A$200.77 A$183.04 −9% vs 215380
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 215380
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 215380

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

WOOJUNG BIO Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "WOOJUNG BIO Inc Fair Value". https://www.fairvalue-calculator.com/stock/215380

Frequently asked questions

Is WOOJUNG BIO Inc (215380) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 903.99 KRW versus a price of 1,874 KRW, about 52% lower (overvalued).
What is the fair value of 215380?
Our model-based fair value for WOOJUNG BIO Inc is 903.99 KRW (as of Nov 3, 2026), built from audited fundamentals. The current price: 1,874 KRW.
What is the quality score of 215380?
WOOJUNG BIO Inc has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for WOOJUNG BIO Inc (215380)?
Our model-based price target is the fair value of 903.99 KRW (as of Nov 3, 2026) from 1 valuation models. Cautious scenario 674.62 KRW, optimistic scenario 1,349 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the WOOJUNG BIO Inc stock forecast for 2026?
Our models put fair value at 903.99 KRW, about 52% lower versus a price of 1,874 KRW (overvalued). Cautious scenario 674.62 KRW, optimistic scenario 1,349 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of WOOJUNG BIO Inc (215380)?
WOOJUNG BIO Inc reported trailing-twelve-month revenue of about 40.3B KRW (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of WOOJUNG BIO Inc (215380)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For WOOJUNG BIO Inc it is 903.99 KRW per share (as of Nov 3, 2026), against a price of 1,874 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is WOOJUNG BIO Inc stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 215380 trades above its calculated fair value: price 1,874 KRW, fair value 903.99 KRW, a gap of about −52% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 215380?
No. The price is what the market pays today (1,874 KRW); the fair value is what the company's own numbers justify (903.99 KRW). For WOOJUNG BIO Inc the two are 970.01 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is WOOJUNG BIO Inc worth?
The market values WOOJUNG BIO Inc at about 30.7B KRW (market capitalisation, as of Nov 3, 2026). Per share that is 1,874 KRW; our models calculate a fair value of 903.99 KRW per share.
What do the bullish and bearish scenarios say about 215380?
Our models span a range for WOOJUNG BIO Inc: cautious scenario 674.62 KRW, base 903.99 KRW, optimistic 1,349 KRW per share (as of Nov 3, 2026, price 1,874 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of WOOJUNG BIO Inc (215380)?
Balance-sheet figures for WOOJUNG BIO Inc (as of Nov 3, 2026): return on equity −14.6%, debt of 1.31 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is 215380 from its 52-week high?
WOOJUNG BIO Inc trades at 1,874 KRW, about 48% below its 52-week high of 3,605 KRW and 6% above the low of 1,761 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 903.99 KRW is for.
Which stocks are comparable to WOOJUNG BIO Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is WOOJUNG BIO Inc stock attractive at the current price?
The data as of Nov 3, 2026: price 1,874 KRW, calculated fair value 903.99 KRW (−52%), Quality Score 24/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 215380 calculated?
We run WOOJUNG BIO Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 903.99 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. WOOJUNG BIO Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of WOOJUNG BIO Inc (215380)?
The closing price on Nov 6, 2026 was 1,874 KRW. Our model-based fair value is 903.99 KRW, about 52% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with WOOJUNG BIO Inc right now?
The price sits above even our optimistic bull case (1,349 KRW). The favourable scenario is already priced in. Weak quality (24/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (674.62 KRW to 1,349 KRW) leaves room in how you read the outcome.

Key figures of WOOJUNG BIO Inc

How large is the market capitalisation of WOOJUNG BIO Inc (215380)?
The market capitalisation of WOOJUNG BIO Inc is 30.7B KRW (≈ $22.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of WOOJUNG BIO Inc (215380)?
The price-to-sales ratio of WOOJUNG BIO Inc is 0.86 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of WOOJUNG BIO Inc (215380)?
Earnings per share at WOOJUNG BIO Inc are −220.56 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of WOOJUNG BIO Inc (215380)?
The net margin of WOOJUNG BIO Inc is −9.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of WOOJUNG BIO Inc (215380)?
The return on equity (ROE) of WOOJUNG BIO Inc is −14.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of WOOJUNG BIO Inc (215380)?
On an EBIT basis the return on assets of WOOJUNG BIO Inc is −3.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of WOOJUNG BIO Inc (215380)?
The operating margin of WOOJUNG BIO Inc is 3.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at WOOJUNG BIO Inc (215380)?
Revenue at WOOJUNG BIO Inc is growing +32.7% versus a year earlier (3y avg −7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at WOOJUNG BIO Inc (215380)?
Earnings per share at WOOJUNG BIO Inc are growing −87.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does WOOJUNG BIO Inc (215380) generate?
The free cash flow of WOOJUNG BIO Inc is −890M KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does WOOJUNG BIO Inc (215380) carry?
The net debt of WOOJUNG BIO Inc is 46.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch WOOJUNG BIO Inc in the live analysis

One click puts WOOJUNG BIO Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.